Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Boehringer Ingelheim
National Cancer Institute (NCI)
USWM, LLC (dba US WorldMeds)
Pfizer
Conjupro Biotherapeutics, Inc.
Pfizer
EpiBiologics
Pfizer
Dragonfly Therapeutics
Aktis Oncology, Inc.
ViroMissile, Inc.
AstraZeneca
Tizona Therapeutics, Inc
ALX Oncology Inc.
UNC Lineberger Comprehensive Cancer Center
SN BioScience
Oscotec Inc.
Boehringer Ingelheim
Novartis
Bolt Biotherapeutics, Inc.
Actym Therapeutics, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Memgen, Inc.
Exelixis
MacroGenics
Incyte Corporation
Genentech, Inc.
Celldex Therapeutics
DEKA Biosciences
Columbia University
Thomas Jefferson University
Revolution Medicines, Inc.
Checkpoint Therapeutics, Inc.
BeiGene
Carisma Therapeutics Inc
Jacobio Pharmaceuticals Co., Ltd.
Acepodia Biotech, Inc.
Inhibrx Biosciences, Inc
Taiho Pharmaceutical Co., Ltd.
Suzhou Genhouse Bio Co., Ltd.
Xencor, Inc.
Pfizer
Pfizer
Celldex Therapeutics
Ikena Oncology
STCube, Inc.
Wellmarker Bio
Yale University
Adaptimmune